Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...

(RTTNews) - Hikma Pharmaceuticals plc (HIK, HIK.L) announced Tuesday that it has entered an exclusive commercial partnership with Emergent BioSolutions for the sale of KLOXXADO naloxone HCl nasal ...

KLOXXADO is a prescription 8 mg naloxone nasal spray designed for the emergency treatment of opioid overdose. The agreement expands Emergent's portfolio of life-saving opioid overdose treatments ...